drugset / Trial / NCT07682272
A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma with intermediate or high recurrence risk.
Timeline
- Start
- 2026-07
- Primary completion
- 2027-07
- Completion
- 2029-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SHR-8068 | Monoclonal antibody | — | — |
| Background | Adebrelimab | Monoclonal antibody | — | — |
| Background | Rivoceranib | Small molecule | — | — |